Abstract
The authors investigated the effect of oxcarbazepine on cognitive function in children and adolescents (6 to younger than 17 years of age) with newly diagnosed partial seizures in an open-label comparison with standard antiepileptic drug therapy (carbamazepine and valproate). No differences in cognitive tests were observed between oxcarbazepine and carbamazepine/valproate over a 6-month treatment period.
| Original language | English |
|---|---|
| Pages (from-to) | 679-682 |
| Number of pages | 4 |
| Journal | Neurology |
| Volume | 67 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2006 |
Fingerprint
ASJC Scopus subject areas
- Neuroscience(all)
Cite this
Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. / Donati, F.; Gobbi, G.; Campistol, J.; Rapatz, G.; Daehler, M.; Sturm, Y.; Aldenkamp, A. P.
In: Neurology, Vol. 67, No. 4, 08.2006, p. 679-682.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures
AU - Donati, F.
AU - Gobbi, G.
AU - Campistol, J.
AU - Rapatz, G.
AU - Daehler, M.
AU - Sturm, Y.
AU - Aldenkamp, A. P.
PY - 2006/8
Y1 - 2006/8
N2 - The authors investigated the effect of oxcarbazepine on cognitive function in children and adolescents (6 to younger than 17 years of age) with newly diagnosed partial seizures in an open-label comparison with standard antiepileptic drug therapy (carbamazepine and valproate). No differences in cognitive tests were observed between oxcarbazepine and carbamazepine/valproate over a 6-month treatment period.
AB - The authors investigated the effect of oxcarbazepine on cognitive function in children and adolescents (6 to younger than 17 years of age) with newly diagnosed partial seizures in an open-label comparison with standard antiepileptic drug therapy (carbamazepine and valproate). No differences in cognitive tests were observed between oxcarbazepine and carbamazepine/valproate over a 6-month treatment period.
UR - http://www.scopus.com/inward/record.url?scp=33747661652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747661652&partnerID=8YFLogxK
U2 - 10.1212/01.wnl.0000230138.46508.5b
DO - 10.1212/01.wnl.0000230138.46508.5b
M3 - Article
C2 - 16924022
AN - SCOPUS:33747661652
VL - 67
SP - 679
EP - 682
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 4
ER -